Luye Pharma Group, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Luye Pharma Group, Ltd.
Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar
Boan Biotech is continuing its ascent in Chinese biosimilars by filing another product with the country’s regulator.
Luye Claims A First With Chinese Denosumab Approval
Luye Pharma has claimed a world first after its Boan Biotech subsidiary obtained an approval from China’s NMPA for its Boyoubei denosumab biosimilar rival to Amgen’s Prolia.
October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Beijing WBL Peking University Biotech Co., Ltd
- Nanjing Luye Sike Pharma Co., Ltd
- Shandong Luye Pharmaceutical Co., Ltd
- Sichuan Luye Baoguang Pharmaceutical Industry Co., Ltd
- Shandong Boan Biological Technology Co. Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.